SLC5A2 and polycythemia: Thromboembolic events have been reported in 2.4%–10% of SGLT-2 inhibitor-related cases, but their causal link to drug-induced erythrocytosis remains unconfirmed, and population-specific baseline risks are poorly characterized [15].